# Innosuisse

> Innosuisse is a VC fund in Berne backing Health Care and Biotechnology. See 236 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Berne, Switzerland
- Total investments: 236
- Last investment: Jul 2026
- Lead investor: 79%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/innosuisse
- X (Twitter): https://twitter.com/_Innosuisse
- Website: https://www.innosuisse.ch
- Facebook: https://www.facebook.com/pg/InnosuisseSwissInnovationAgency

Innosuisse is a VC fund in Berne focused on Health Care and Biotechnology. Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.

## Contacts

5 contacts available for Innosuisse. Shizune tracks 15 team members at Innosuisse. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/innosuisse?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $500k–$16M |
| Grant | $41k–$2.5M |
| Pre-Seed | $16k–$4.3M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 45 | 19% |
| Biotechnology | 39 | 17% |
| Medical Device | 31 | 13% |
| Medical | 30 | 13% |
| Software | 27 | 11% |

173 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 184 | 78% |
| Pre-Seed | 11 | 5% |
| Seed | 6 | 3% |
| Funding Round | 1 | 0% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 184 | 78% |
| United States | 7 | 3% |
| United Kingdom | 3 | 1% |
| Taiwan | 1 | 0% |
| Germany | 1 | 0% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrea Schlapbach | Start-up Coach | 0 | https://shizune.co/investors/profile/andrea-schlapbach |
| Andreas Jurgeit | Coach and Lecturer | 5 | https://shizune.co/investors/profile/andreas-jurgeit |
| Andre Kudelski | Founder and President | 0 | https://shizune.co/investors/profile/andre-kudelski |
| Balz Roth | Startup Coach | 32 | https://shizune.co/investors/profile/balz-roth |
| Carmelo Bisognano | Expert for Innosuisse | 0 | https://shizune.co/investors/profile/carmelo-bisognano |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Actival | Actival is driven by innovation and the integration of AI tools in dentistry. It is committed to precision and oral health. | $1.7M | Grant | Jul 20, 2026 |  |
| Precise Health | Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to end the threat of antimicrobial resistance through an AI-powered technology. | $1.1M | Grant | Jun 15, 2026 |  |
| BLEEDnFIRE Therapeutics | BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments |  | Grant | May 27, 2026 |  |
| OrthoSens | OrthoSens develops battery-free sensors that turn standard orthopedic implants into smart, data-driven devices. Unlike existing smart implant solutions that require an implanted battery making them too large and too risky to scale beyond large joints, OrthoSens moves all electronics outside the body. A paper-thin sensor integrates directly intoexisting implants with no battery, no surgical workflow change and zero explant risk. An external wearable powers the sensor wirelessly and collects real-time data on load, micromotion and bone fusion. The result is a footprint 250x smaller than battery-powered competitors, opening up additional spine, foot & ankle markets that existing solutions cannot address. The clinical need is clear: approximately 20% of post-surgical patients drive around 68% of total post-operative costs through missed complications, continuous implant monitoring exists to catch them earlier. Starting January 2026, 745 US hospitals enrolled in CMS's mandatory TEAM bundle are now accountable for 30-day episode costs, creating direct institutional demand for this data.OrthoSens generates revenue through three streams: sensor sales to orthopedic implant manufacturers (unlocking +$1,309 NTAP reimbursement per unit), a SaaS subscription capturing 40% of Medicare's $104/month RPM reimbursement per patient and post-market data analytics. The company has validated its technology across 3 functional prototypes, filed 2 core patents with favorable Freedom to Operate and secured $1.3M+ in non-dilutive funding. It is raising a $2.3M seed round to complete ISO-13485 certification, conduct the FDA pre-clinical study and file a 510(k) submission. The team is led by Gwenael Hannema (3x medtech founder), Dr. Oleg Kotsur (Head of R&D), and key employees, supported by experienced board members with leadership backgrounds at Novartis, Medtronic and J&J MedTech. | $1.1M | Grant | Mar 20, 2026 |  |
| Chiral | Next-generation electronics with nanomaterials | $12M | Seed | Feb 05, 2026 |  |
| Sparkli | Sparkli offers an AI-powered educational platform that turns children’s questions into interactive learning journeys called “expeditions.” The platform generates multimodal content blending visuals, audio narration, games, and quizzes to help learners explore topics and build skills like design thinking, financial literacy, sustainability, andemotional intelligence. It personalizes experiences using generative AI so that young learners engage with content aligned to their curiosity and interests. Sparkli also includes features to track progress and encourage regular engagement through challenges, rewards, and creative reflections. The platform supports both individual exploration and guided learning contexts for children. |  | Grant | Jan 26, 2026 |  |
| Reverso Therapeutics | Reverso medicines is a biotechnology company that offers therapeutic medicines for anticoagulant therapy. | $901.5K | Grant | Dec 23, 2025 |  |
| EVis Bioscience | EVis Bioscience offers gene delivery solutions using extracellular vesicles, lipid nanoparticles, and hybrid systems. | $391K | Grant | Dec 16, 2025 |  |
| Lighthouse Tech | This pioneering smart eyewear addresses a fast-growing global need: enhancing safety and independence for people who are blind or visually impaired. Using advanced front-facing sensors, TAMI® scans the environment in real time and alerts wearers to obstacles above the waist—areas the white cane cannot cover—unlocking an untapped market segment inassistive mobility. The frame integrates processors, Bluetooth connectivity, and a rechargeable battery seamlessly into the temples. At only 55g, it remains lightweight, waterproof, and impact-resistant, built to withstand sunlight, rain, and snow. This durability ensures consistent performance across geographies, making it suitable for mass adoption. In combination with the white cane, it provides complete protection, positioning the product as a natural complement rather than a replacement. Design is equally strategic. Offered in three sleek models in 4 colors,TAMI® directly challenges the stigma surrounding assistive devices, which are typically bulky or outdated. By making accessibility fashionable, it becomes an attractive lifestyle product, opening the door to broader acceptance and adoption. Onboarding is frictionless: with less than 30 minutes of training, users can operate it confidently. This ease of use accelerates uptake across demographics, including those less familiar with technology. It represents a scalable solution in the assistive tech sector, combining intuitive operation with strong everyday utility. By merging advanced obstacle detection with consumer-driven design, the eyewear sets a new standard in mobility aids. This balance of function and fashion is critical for global scaling, enabling partnerships with established eyewear and healthcare brands while empowering users worldwide with confidence, independence, and social inclusion. | $1.5M | Grant | Dec 02, 2025 |  |
| Dexterous Endoscopes | We are developing endoscopes with variable stiffness, providing high control and advanced tissue dissection capabilities, enabling new types of minimally invasive procedures in sinuses, larynxes, and beyond. | $534.3K | Grant | Dec 01, 2025 |  |

10 of 236 investments shown.

## Co-investors
- [Gebert Rüf Stiftung](https://shizune.co/investors/profile/gebert-r%C3%BCf-stiftung) — VC Fund, 4 deals together
- [Innovate UK](https://shizune.co/investors/profile/innovate-u-k-) — VC Fund, 4 deals together
- [Venture Kick](https://shizune.co/investors/profile/venturekick) — VC Fund, 4 deals together
- [Eurostars](https://shizune.co/investors/profile/eurostars) — VC Fund, 3 deals together
- [Founderful](https://shizune.co/investors/profile/wingman-897a) — VC Fund, 3 deals together
- [EIT Health](https://shizune.co/investors/profile/eit-health) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [All Investors in Switzerland](https://shizune.co/investors/investors-switzerland)
- [All VC Funds in Switzerland](https://shizune.co/investors/vc-funds-switzerland)
- [SaaS Investors in Switzerland](https://shizune.co/investors/saas-investors-switzerland)
- [SaaS VC Funds in Switzerland](https://shizune.co/investors/saas-vc-funds-switzerland)
- [Software Investors in Switzerland](https://shizune.co/investors/software-investors-switzerland)
- [Software VC Funds in Switzerland](https://shizune.co/investors/software-vc-funds-switzerland)

## FAQ

### What does Innosuisse invest in?

Innosuisse invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Grant and Pre-Seed stage. Most of the 236 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Innosuisse's check size?

Innosuisse typically joins rounds of $500k–$16M at Seed, $41k–$2.5M at Grant and $16k–$4.3M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Innosuisse participates in.

### How do I contact Innosuisse?

Public channels for Innosuisse include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Innosuisse?

The team at Innosuisse includes Andrea Schlapbach (Start-up Coach), Andreas Jurgeit (Coach and Lecturer) and Andre Kudelski (Founder and President), among 15 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co